154 results on '"Michael S. Ritsner"'
Search Results
2. Patients' satisfaction with hospital health care: Identifying indicators for people with severe mental disorder
- Author
-
Xavier Zendjidjian, Nina Mendyk, Igor Timinsky, Yael Ratner, and Michael S. Ritsner
- Subjects
Adult ,Male ,medicine.medical_specialty ,Anhedonia ,Family support ,Psychological intervention ,Schizoaffective disorder ,03 medical and health sciences ,Social support ,0302 clinical medicine ,Quality of life (healthcare) ,Surveys and Questionnaires ,Health care ,Humans ,Medicine ,030212 general & internal medicine ,Psychiatry ,Biological Psychiatry ,Inpatients ,business.industry ,Social Support ,Middle Aged ,medicine.disease ,Mental illness ,Self Concept ,Self Efficacy ,030227 psychiatry ,Psychiatry and Mental health ,Psychotic Disorders ,Patient Satisfaction ,Quality of Life ,Female ,Schizophrenic Psychology ,business ,Personality ,Psychopathology - Abstract
Background Patients’ perception of psychiatric healthcare is a critical indicator in measuring service quality. The aim of the study was to determine patient's level of satisfaction with the quality of health care delivered at the inpatient departments, and to identify the service quality factors that were important to patients. Method The Satisfaction with Psychiatry Care Questionnaire-22 was administered to 125 consecutive inpatients with schizophrenia or schizoaffective disorder in a stable condition. Sociodemographic and background variables, illness and symptom severity, insight, social anhedonia, self-esteem, perceived social support, and satisfaction with quality of life were collected. Results Although the participants generally expressed satisfaction with the inpatient services, they indicated that the weakest aspects of the service were in the domains of ‘personal experience’, ‘information’ and ‘activity’. Women were significantly more dissatisfied than men with ‘staff’, ‘care’, and by general satisfaction. Multiple regression analysis revealed that satisfaction with hospital health care was associated with five indicators: insight, satisfaction with physical health, self-efficacy, family support, and social anhedonia. Conclusion Personality related factors rather than psychopathological symptoms were associated with a satisfaction with care of admitted patients with severe mental illness. These factors could be targets for interventions aimed to improve treatment and hospital services.
- Published
- 2018
3. Predicting Predischarge Anhedonia Among Inpatients With Schizophrenia and Schizoaffective Disorders: A Large-scale Analysis
- Author
-
Michael S. Ritsner and Yael Ratner
- Subjects
Adult ,Male ,medicine.medical_specialty ,Anhedonia ,media_common.quotation_subject ,Pleasure ,03 medical and health sciences ,Social support ,Young Adult ,0302 clinical medicine ,Risk Factors ,medicine ,Humans ,Psychology ,Psychological testing ,Psychiatry ,media_common ,Psychiatric Status Rating Scales ,Psychological Tests ,business.industry ,Middle Aged ,Mental illness ,medicine.disease ,Patient Discharge ,030227 psychiatry ,Psychiatry and Mental health ,Distress ,Cross-Sectional Studies ,Psychotic Disorders ,Schizophrenia ,Female ,Schizophrenic Psychology ,medicine.symptom ,business ,Psychosocial ,030217 neurology & neurosurgery - Abstract
This study sought to evaluate predischarge anhedonia level and its predictors in 125 inpatients with schizophrenia and schizoaffective disorders. Consecutively admitted inpatients were assessed before discharge from the hospital using the Specific Loss of Interest and Pleasure Scale (SLIPS) and a battery of measures for clinical and psychosocial variables. When symptoms, distress, and social anhedonia scores were controlled, the SLIPS score inversely correlated with self-constructs, social support, quality of life, recovery, and unmet needs. Using two cutoff points of the data set of SLIPS, we identified three groups: 19 (15.2%) patients reported "no loss of pleasure"; 46 (36.8%), "some loss of pleasure"; and 60 (48.0%), "marked diminishment of pleasure." The SLIPS score is predicted by sensitivity, unmet needs, deficient interpersonal pleasure, poor quality of life, and friend support. The study underlines the importance of assessing anhedonia and related psychosocial factors in patients with serious mental illness.
- Published
- 2018
4. The characterization of social anhedonia and its correlates in schizophrenia and schizoaffective patients
- Author
-
Diane C. Gooding, Nina Mendyk, Yael Ratner, and Michael S. Ritsner
- Subjects
Adult ,Male ,Pleasure ,Anhedonia ,media_common.quotation_subject ,Concurrent validity ,Schizoaffective disorder ,03 medical and health sciences ,Social support ,0302 clinical medicine ,Quality of life ,medicine ,Humans ,Biological Psychiatry ,media_common ,Psychopathology ,Self-esteem ,Social Support ,Middle Aged ,medicine.disease ,Self Concept ,Self Efficacy ,030227 psychiatry ,Psychiatry and Mental health ,Psychotic Disorders ,Schizophrenia ,Quality of Life ,Female ,Schizophrenic Psychology ,Self Report ,medicine.symptom ,Psychology ,030217 neurology & neurosurgery ,Clinical psychology - Abstract
Although social hedonic capacity is often assessed in clinical settings, its operational definitions have not been evaluated for concurrent validity. One hundred and twenty-five patients with schizophrenia and schizoaffective disorder were classified according to their self-reported social hedonic functioning into three groups on the basis of their total scores on the Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS). Participants were assessed before discharge using questionnaires and psychiatric rating scales. Using an empirically based cutoff score, we identified three groups: an intact social hedonic group (WNL), a socially anhedonic group (SA), and a socially hypohedonic group (i.e., those with scores intermediate between normal functioning and aberrantly low functioning, H). The SA patients were significantly different from the two other groups (WNL and H) by their higher severity of psychopathology, lower levels of self-efficacy, and less self-esteem. The SA patients also reported less perceived social support, poorer quality of life, and less subjective recovery. Our findings indicate that social anhedonia is a meaningful target for intervention. Further implications of our findings are discussed.
- Published
- 2018
5. Assessment of health needs, satisfaction with care, and quality of life in compulsorily admitted patients with severe mental disorders
- Author
-
Avi Amrami-Weizman, Xavier Zendjidjian, Boris Rauchberger, Herman Farkash, and Michael S. Ritsner
- Subjects
Adult ,Male ,medicine.medical_specialty ,Family support ,media_common.quotation_subject ,Psychological intervention ,Schizoaffective disorder ,03 medical and health sciences ,Social support ,0302 clinical medicine ,Quality of life (healthcare) ,Patient Admission ,Surveys and Questionnaires ,Medicine ,Humans ,Psychiatry ,Biological Psychiatry ,media_common ,Health Services Needs and Demand ,business.industry ,Mental Disorders ,Anhedonia ,Social Support ,Middle Aged ,medicine.disease ,Involuntary Treatment ,030227 psychiatry ,Hospitalization ,Psychiatry and Mental health ,Cross-Sectional Studies ,Feeling ,Schizophrenia ,Patient Satisfaction ,Quality of Life ,Female ,medicine.symptom ,business ,030217 neurology & neurosurgery - Abstract
This cross-sectional study compared the levels of needs, care satisfaction, quality of life, and social support of compulsory admitted patients with severe mental disorders to a comparable group of voluntary admitted patients. One hundred and twenty-five patients with schizophrenia and schizoaffective disorder were admitted to a hospital by district psychiatrist order (DPO), court observation order (COO), or voluntary (VA). Participants were assessed before discharge using questionnaires, and psychiatric rating scales. A linear discriminant analysis revealed eight variables that best differentiated the three groups. COO patients were significantly discriminated from the two other groups (DPO and VA) by severe negative symptoms, better satisfaction with both nursing staff and family support. COO subjects had more non-illness unmet needs, while reported better hedonic capacity for social and interpersonal pleasure – compared to VA patients. DPO patients were significantly indicated by poorer awareness to illness, but better satisfaction with subjective feelings. VA subjects were significantly discriminated from compulsory admitted patients by higher illness severity scores. Assessment of unmet needs, satisfaction with care, quality of life, hedonic capacity, and social support constitute the factors that differentiate compulsory admitted patients and could be targets for interventions aimed to reduce the negative effects of compulsory admissions.
- Published
- 2018
6. Short-Term Hospitalization Underlies the Similarity between Involuntarily and Voluntarily Admitted Patients: A One-Year Cohort Study
- Author
-
Alexander Grinshpoon, Michael S. Ritsner, and Rena Kurs
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,Health Policy ,Public Health, Environmental and Occupational Health ,Mental health ,Psychiatry and Mental health ,Cohort ,Marital status ,Medicine ,Psychiatric hospital ,Involuntary commitment ,Age of onset ,medicine.symptom ,business ,Major depressive episode ,Cohort study - Abstract
This study compared individuals admitted to a psychiatric hospital under a civil involuntary commitment order (IA) and patients admitted voluntarily (VA) using a one-year, shortest-stay cohort. Data were collected for 439 patients consecutively admitted to a university-affiliated Mental Health Center from March 1, 2012, to February 28, 2013, and discharged within seven days (one-year, shortest-stay cohort). A cross-sectional comparison between IA (n = 106) and VA (n = 333) groups was conducted. Mean length-of-stay was found to be slightly longer (4.7 ± 1.7 days) for the IA group compared to the VA group (3.8 ± 1.9 days; p = 0.019). Both IA and VA groups were similar regarding age, gender, marital status, age of onset, illness duration, and diagnosis. An acute psychotic state as reason for admission was observed 3.4 times more (p
- Published
- 2014
7. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: An 8-week, double-blind, randomized add-on two-center trial
- Author
-
Hisham Bawakny, Anatoly Kreinin, and Michael S. Ritsner
- Subjects
medicine.medical_specialty ,General Neuroscience ,medicine.medical_treatment ,Anhedonia ,Schizoaffective disorder ,General Medicine ,medicine.disease ,Placebo ,Psychiatry and Mental health ,Mood ,Neurology ,Schizophrenia ,Internal medicine ,medicine ,Pregnenolone ,Neurology (clinical) ,medicine.symptom ,Psychiatry ,Antipsychotic ,Psychology ,Avolition ,medicine.drug - Abstract
Aims Management of recent-onset schizophrenia (SZ) and schizoaffective disorder (SA) is challenging owing to frequent insufficient response to antipsychotic agents. This study aimed to test the efficacy and safety of the neurosteroid pregnenolone in patients with recent-onset SZ/SA. Methods Sixty out- and inpatients who met DSM-IV criteria for SZ/SA, with suboptimal response to antipsychotics were recruited for an 8-week, double-blind, randomized, placebo-controlled, two-center add-on trial, that was conducted between 2008 and 2011. Participants were randomized to receive either pregnenolone (50 mg/day) or placebo added on to antipsychotic medications. The primary outcome measures were the Positive and Negative Symptoms Scale and the Assessment of Negative Symptoms scores. Secondary outcomes included assessments of functioning, and side-effects. Results Analysis was by linear mixed model. Fifty-two participants (86.7%) completed the trial. Compared to placebo, adjunctive pregnenolone significantly reduced Positive and Negative Symptoms Scale negative symptom scores with moderate effect sizes (d = 0.79). Significant improvement was observed in weeks 6 and 8 of pregnenolone therapy among patients who were not treated with concomitant mood stabilizers (arms × visit × mood stabilizers; P = 0.010). Likewise, pregnenolone significantly reduced Assessment of Negative Symptoms scores compared to placebo (d = 0.57), especially on blunted affect, avolition and anhedonia domain scores. Other symptoms, functioning, and side-effects were not significantly affected by adjunctive pregnenolone. Antipsychotic agents, benzodiazepines and sex did not associate with pregnenolone augmentation. Pregnenolone was well tolerated. Conclusions Thus, add-on pregnenolone reduces the severity of negative symptoms in recent-onset schizophrenia and schizoaffective disorder, especially among patients who are not treated with concomitant mood stabilizers. Further studies are warranted.
- Published
- 2014
8. Predicting 10-year quality-of-life outcomes of patients with schizophrenia and schizoaffective disorders
- Author
-
Alexander Grinshpoon, Michael S. Ritsner, and Alexander Lisker
- Subjects
medicine.medical_specialty ,General Neuroscience ,Life satisfaction ,Schizoaffective disorder ,General Medicine ,Odds ratio ,Logistic regression ,medicine.disease ,Psychiatry and Mental health ,Distress ,Neurology ,Quality of life ,Schizophrenia ,medicine ,Neurology (clinical) ,Psychology ,Psychiatry ,Psychosocial ,Clinical psychology - Abstract
Aims This study aimed to determine predictors for 10-year good versus poor perceived general quality of life (QOL) outcomes from baseline variables in people with schizophrenia and schizoaffective disorder. Methods We compared patients with poor versus good 10-year QOL outcomes using baseline clinical, personality-related variables, demographic and background characteristics. Logistic regression analysis was used for predicting the 10-year QOL outcomes from baseline data. One-hundred-eight patients completed the Quality-of-Life Enjoyment and Life Satisfaction Questionnaire, the Positive and Negative Syndromes Scale (PANSS), the Talbieh Brief Distress Inventory, and psychosocial questionnaires at baseline and 10 years later. Results Logistic regression revealed six predictors of QOL outcomes: paranoid ideations (odds ratio [OR] 3.1), PANSS general psychopathology (OR 1.1), obsessiveness (OR 0.84), hostility (OR 0.4), PANSS positive scale scores (OR 0.4), and general QOL index (OR 0.4). This model classified 80.6% of the sample with good sensitivity (87% correctly identified ‘poor outcome’), and specificity (71% correctly identified ‘good outcome’). Conclusion This study provides a pattern of baseline predictors for long-term QOL outcomes. Identified predictors are factors that can potentially be ameliorated, and thereby enhance the QOL of people with schizophrenia and schizoaffective disorder.
- Published
- 2014
9. Symptom severity scale of the DSM5 for schizophrenia, and other psychotic disorders: diagnostic validity and clinical feasibility
- Author
-
Alexander Grinshpoon, Maria Mar, Marina Arbitman, and Michael S. Ritsner
- Subjects
Adult ,Male ,medicine.medical_specialty ,Psychometrics ,Severity of Illness Index ,Cronbach's alpha ,medicine ,Humans ,Psychiatry ,Biological Psychiatry ,Aged ,Positive and Negative Syndrome Scale ,Reproducibility of Results ,Middle Aged ,medicine.disease ,Diagnostic and Statistical Manual of Mental Disorders ,Psychiatry and Mental health ,Cross-Sectional Studies ,Psychotic Disorders ,Mood disorders ,Convergent validity ,Schizophrenia ,Feasibility Studies ,Female ,medicine.symptom ,Factor Analysis, Statistical ,Psychology ,Mania ,Diagnosis of schizophrenia ,Clinical psychology - Abstract
Innovations in DSM5 include dimensional diagnosis of schizophrenia (SZ) and other psychotic (OP) disorders using the symptom severity scale (SS-DSM5). We evaluated the psychometric properties and diagnostic validity of the SS-DSM5 scale using a cross-sectional design and an unselected convenience unselected sample of 314 inpatients and outpatients with SZ/OP and mood disorders who received standard care in routine clinical practice. The SS-DSM5 scale, the Clinical Global Impression-Severity scale (CGI-S), the Positive and Negative Syndrome Scale (PANSS), and the Bech-Rafaelsen Mania Scale (BRMS) were administered. Factor structure, reliability, internal consistency, convergent and diagnostic ability of the DSM5-SS were evaluated. Factor analysis indicated two latent factors underlying the SS-DSM5 (Psychotic and Deficit sub-scales). Cronbach's alpha was >0.70. Convergent validity of the SS-DSM5 was highly significant. Patients with SZ/PO disorders were correctly diagnosed (77.9%) using the SS-DSM5 scale (72% using PANSS). The agreement of the diagnostic decisions between the SS-DSM5 and PANSS was substantial for SZ/PO disorders (Kappa=0.75). Classifying participants with SZ/PO versus mood disorders using SS-DSM5 provided a sensitivity of 95%, and specificity of 34%. Thus, this study suggests that the SS-DSM5 has acceptable psychometric properties and that its use in clinical practice and research is feasible in clinical settings. The dimensional option for the diagnosis of schizophrenia and related disorders using SS-DSM5 is discussed.
- Published
- 2013
10. Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date
- Author
-
Michael S. Ritsner, Vladimir Lerner, and Peter McCaffery
- Subjects
0301 basic medicine ,medicine.drug_class ,Receptors, Retinoic Acid ,Retinoic acid ,Schizoaffective disorder ,Tretinoin ,Pharmacology ,Bioinformatics ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,medicine ,Animals ,Humans ,Pharmacology (medical) ,Retinoid ,Bexarotene ,Brain ,medicine.disease ,Clinical trial ,Psychiatry and Mental health ,030104 developmental biology ,chemistry ,Schizophrenia ,Neurology (clinical) ,Psychopharmacology ,Psychology ,030217 neurology & neurosurgery ,medicine.drug ,Antipsychotic Agents - Abstract
This review provides the rationale and reports on the progress to date regarding the targeting of retinoid receptors for the treatment of schizophrenia and schizoaffective disorder and the role of retinoic acid in functions of the normal brain, and in psychotic states. After a brief introduction, we describe the normal function of retinoic acid in the brain. We then examine the evidence regarding retinoid dysregulation in schizophrenia. Finally, findings from two add-on clinical trials with a retinoid (bexarotene) are discussed. The authors of this review suggest that targeting retinoid receptors may be a novel approach to treat schizophrenia and schizoaffective disorder. Further studies are warranted.
- Published
- 2016
11. Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factors
- Author
-
Marina Arbitman, Michael S. Ritsner, and Alexander Lisker
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Psychometrics ,Global Assessment of Functioning ,Personal Satisfaction ,Severity of Illness Index ,Statistics, Nonparametric ,Young Adult ,Quality of life ,Predictive Value of Tests ,Surveys and Questionnaires ,Adaptation, Psychological ,medicine ,Health Status Indicators ,Humans ,Prospective Studies ,Psychiatry ,Analysis of Variance ,Chi-Square Distribution ,Public Health, Environmental and Occupational Health ,Life satisfaction ,Middle Aged ,medicine.disease ,Predictive value ,Distress ,Treatment Outcome ,Psychotic Disorders ,Schizophrenia ,Quality of Life ,Clinical Global Impression ,Female ,Schizophrenic Psychology ,Psychology ,Somatization ,Stress, Psychological ,Clinical psychology - Abstract
To provide data on long-term health-related quality of life (HRQL) outcomes among patients with schizophrenia (SZ) and schizoaffective (SA) disorders and determine the predictive value of disorder-related factors. A total of 108 patients with SZ/SA were assessed during stabilization phase and over 10 years with the Quality of Life Enjoyment and Life Satisfaction Questionnaire (Q-LES-Q), Clinical Global Impression Scale, Positive and Negative Syndromes Scale (PANSS), Distress Scale for Adverse Symptoms (DSAS), Talbieh Brief Distress Inventory (TBDI), Brief Symptom Inventory-Somatization Scale (BSI-S), and Global Assessment of Functioning Scale (GAF). Variability and relationships between Q-LES-Q and disorder-related dimensions over time were analyzed. There were no differences in Q-LES-Q dimensions between patients with SZ and SA disorders. Poor outcomes were found among 76% of the patients with SZ/SA disorders who remained dissatisfied (64%) or worsened (12%) with their HRQL over time. However, 24% of patients reported improved quality of life (16%), or remained satisfied (8%). Changes in TBDI, DSAS, BSI-S, PANSS, and GAF measures accounted for 20–50% of the total variance in satisfaction changes in Q-LES-Q domains across time. Long-term quality of life outcomes are characterized by four different types that fit changes over time in emotional distress, side effects, somatization, symptom dimensions, and general functioning scores. Revealed predictors are factors that can be ameliorated and thereby enhance satisfaction with quality of life over time.
- Published
- 2011
12. The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia
- Author
-
Michael S. Ritsner
- Subjects
Central Nervous System ,medicine.medical_specialty ,Neuroactive steroid ,Dehydroepiandrosterone ,Anxiety ,Neuroprotection ,Internal medicine ,mental disorders ,polycyclic compounds ,medicine ,Humans ,Effects of sleep deprivation on cognitive performance ,Neurotransmitter Agents ,Dehydroepiandrosterone Sulfate ,General Neuroscience ,Drug Synergism ,Human brain ,medicine.disease ,Endocrinology ,medicine.anatomical_structure ,Schizophrenia ,Pregnenolone ,Cognition Disorders ,Psychology ,Neuroscience ,Neurocognitive ,hormones, hormone substitutes, and hormone antagonists ,Antipsychotic Agents ,medicine.drug - Abstract
Neurosteroids such as dehydroepiandrosterone (DHEA), pregnenolone (PREG), and their sulfates (DHEAS and PREGS) display multiple effects on the central nervous system. Specifically, neurosteroids have various functions associated with neuroprotection, response to stress, mood regulation, and cognitive performance. In addition, neurosteroid levels are altered in stress-related neuropsychiatric disorders. This review focuses on the alterations of these neurosteroids in schizophrenia and on their association with clinical and neurocognitive manifestations. As described henceforth, findings from clinical studies have revealed that PREG, DHEA, and their sulfates might be involved in the pathophysiology of schizophrenia, and in some of its manifestations. Clinical trials for the evaluation of these neurosteroids face challenges in terms of experimental design, dosing strategy, data analysis, and interpretation. The review concludes with a list of suggested topics for future research. This article is part of a Special Issue entitled: Neuroactive Steroids: Focus on Human Brain.
- Published
- 2011
13. Health-Related Quality of Life Impairment in Schizophrenia and Related Disorders as a Target for Neuroprotective Therapy
- Author
-
Michael S. Ritsner
- Subjects
Neuroactive steroid ,business.industry ,Cognition ,General Medicine ,medicine.disease ,Neuroprotection ,Distress ,Neurotrophic factors ,Schizophrenia ,mental disorders ,Medicine ,business ,Psychosocial ,Psychopathology ,Clinical psychology - Abstract
Schizophrenia is a chronic, severe, and disabling brain disease. Today the neuroscience and clinical researches have advanced sufficiently to develop neuroprotective approach for discovery a novel generation of compounds with neuroprotective properties. However, the use of neuroprotective agents in schizophrenia is not yet well established. There are two main targets for neuroprotective therapy: (1) neurodegenerative processes in schizophrenia (e.g., apoptosis, excitotoxicity, oxidative stress, stress sensitization, neurotrophic factor expression, and alteration of neurosteroids); and (2) clinical, and behavioral presentations of illness including psychopathological symptoms, a significant decline in cognition, psychosocial functioning and in health related quality of life (HRQL) of patients. The HRQL deficit or impairment is a core feature of schizophrenia spectrum disorders. Based on the author’s and his team research contributions for last ten years, and complementary theoretical considerations, this paper presents the Distress/Protection Vulnerability Model of HRQL impairment in schizophrenia and related disorders. This model has reshaped our understanding of schizophrenia phenotype and will be essential useful for designing more effective clinical and neuroprotective trials.
- Published
- 2010
14. T210. PSYCHOSOCIAL CORRELATES OF INTERPERSONAL PLEASURE IN SCHIZOPHRENIA-SPECTRUM PATIENTS
- Author
-
Michael S. Ritsner, Michael Ermiyev, Diane C. Gooding, Nina Mendyk, Yael Ratner, and Herman Farkash
- Subjects
Psychiatry and Mental health ,Abstracts ,Poster Session I ,media_common.quotation_subject ,Interpersonal communication ,Psychology ,Psychosocial ,Schizophrenia spectrum ,Clinical psychology ,Pleasure ,media_common - Abstract
Background Although many people with schizophrenia-spectrum disorders report high levels of social anhedonia, it is not clear what differentiates those patients who self-report social anhedonia from those who do not. Moreover, the extent to which the hedonic functioning of severely disordered patients is associated with their clinical symptoms or with personality-related factors remains unresolved. Methods We administered the Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS; Gooding & Pflum, 2014), a self-report measure designed to assess hedonic capacity for social and interpersonal pleasure, to 125 consecutively admitted inpatients with schizophrenia-spectrum disorder. The (81 schizophrenia, 44 schizoaffective disordered) patients were assessed in terms of their illness and symptom severity. They were also administered measures of self-efficacy (GSES; Jerusalem & Schwarzer, 1992), quality of life (Q-LES-Q-18; Ritsner et al., 2005), and recovery level (RAS-20; Salzer, 2010). Based on total ACIPS scores, two cut-off points were defined in order to classify participants as ‘normally hedonic’, ‘hypohedonic’ or ‘anhedonic’. Results The ACIPS negatively correlated with 8 PANSS items: conceptual disorganization (P2, r=-0.24, p
- Published
- 2018
15. Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: A multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA
- Author
-
Rael D. Strous and Michael S. Ritsner
- Subjects
Adult ,Male ,Psychosis ,medicine.medical_specialty ,Hydrocortisone ,medicine.medical_treatment ,Radioimmunoassay ,Dehydroepiandrosterone ,Neuropsychological Tests ,Young Adult ,Double-Blind Method ,Internal medicine ,polycyclic compounds ,medicine ,Humans ,Androstenedione ,Antipsychotic ,Biological Psychiatry ,Cross-Over Studies ,Trauma Severity Indices ,Dehydroepiandrosterone Sulfate ,Cognitive disorder ,Middle Aged ,medicine.disease ,Crossover study ,Psychiatry and Mental health ,Endocrinology ,Schizophrenia ,Drug Therapy, Combination ,Female ,Schizophrenic Psychology ,Cognition Disorders ,Psychology ,Neurocognitive ,hormones, hormone substitutes, and hormone antagonists - Abstract
Background While neurosteroids exert multiple effects in the central nervous system, their associations with neurocognitive deficits in schizophrenia are not yet fully understood. The purpose of this study was to identify the contribution of circulating levels of dehydroepiandrosterone (DHEA), its sulfate (DHEAS), androstenedione, and cortisol to neurocognitive deficits through DHEA administration in schizophrenia. Methods Data regarding cognitive function, symptom severity, daily doses, side effects of antipsychotic agents and blood levels of DHEA, DHEAS, androstenedione and cortisol were collected among 55 schizophrenia patients in a double-blind, randomized, placebo-controlled, crossover trial with DHEA at three intervals: upon study entry, after 6 weeks of DHEA administration (200 mg/d), and after 6 weeks of a placebo period. Multiple regression analysis was applied for predicting sustained attention, memory, and executive function scores across three examinations controlling for clinical, treatment and background covariates. Results Findings indicated that circulating DHEAS and androstenedione levels are shown as positive predictors of cognitive functioning, while DHEA level as negative predictor. Overall, blood neurosteroid levels and their molar ratios accounted for 16.5% of the total variance in sustained attention, 8–13% in visual memory tasks, and about 12% in executive functions. In addition, effects of symptoms, illness duration, daily doses of antipsychotic agents, side effects, education, and age of onset accounted for variability in cognitive functioning in schizophrenia. Conclusions The present study suggests that alterations in circulating levels of neurosteroids and their molar ratios may reflect pathophysiological processes, which, at least partially, underlie cognitive dysfunction in schizophrenia.
- Published
- 2010
16. Neurocognitive Effects of Ziprasidone and Related Factors in Patients With Chronic Schizophrenia Undergoing Usual Care
- Author
-
Anatoly Gibel and Michael S. Ritsner
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Administration, Oral ,Severity of Illness Index ,Piperazines ,Cognition ,Extrapyramidal symptoms ,Wisconsin Card Sorting Test ,Rating scale ,medicine ,Humans ,Pharmacology (medical) ,Ziprasidone ,Psychiatry ,Psychiatric Status Rating Scales ,Pharmacology ,Dose-Response Relationship, Drug ,Positive and Negative Syndrome Scale ,Middle Aged ,medicine.disease ,Thiazoles ,Schizophrenia ,Chronic Disease ,Clinical Global Impression ,Female ,Schizophrenic Psychology ,Neurology (clinical) ,medicine.symptom ,Cognition Disorders ,Psychology ,Neurocognitive ,Antipsychotic Agents ,medicine.drug - Abstract
Objective: Two questions were addressed in the present report: whether cognitive improvement would occur during 12-month ziprasidone treatment and whether the changes in cognitive functioning are dependent of changes in the illness-related variables. Methods: Seventy schizophrenia patients with persistent symptoms or troublesome side effects were assigned to a 12-month, open-label, flexible-dosage (40-160 mg/d) trial. Outcome measures were taken at baseline, 6, and 12 months and included the Mindstreams Computerized Cognitive Battery, the Wisconsin Card Sorting Test, the Clinical Global Impression Scale, the Positive and Negative Syndrome Scale, and the Extrapyramidal Symptom Rating Scale. Results: Baseline performance was impaired across all cognitive tasks on average without significant differences between 32 completers and 38 discontinued patients. At the end of the study, significant improvement in performance of executive functions, attention, and information processing domains among ziprasidone-completed patients was observed. The effect sizes for these changes were moderate (0.61). Improvement in the executive performances was associated with a reduction in the severity of positive, activation, and dysphoric mood symptoms but was unrelated to the ziprasidone daily dose, Clinical Global Impression Scale and Extrapyramidal Symptom Rating Scale scores, and concomitantly prescribed antidepressants, anxiolytics, mood stabilizers, or anti-parkinson drugs. Conclusions: Ziprasidone had a long-term neurocognitive effect among patients with chronic schizophrenia undergoing the usual care. This effect tended to increase over time and was associated, at least partly, with changes in symptoms, but not with changes in the severity of illness, side effects, the ziprasidone daily dose, and concomitant medicines. Abbreviations: CGI-S, Clinical Global Impression Scale, ESRS, Extrapyramidal Symptom Rating Scale, FGAs, first-generation antipsychotic agents, Mindstreams, Mindstreams Computerized Cognitive Battery, PANSS, Positive and Negative Syndromes Scale, SGAs, second-generation antipsychotic agents, WCST, Wisconsin Card Sorting Test.
- Published
- 2008
17. Anhedonia: A Comprehensive Handbook Volume II : Neuropsychiatric And Physical Disorders
- Author
-
Michael S. Ritsner and Michael S. Ritsner
- Subjects
- Affective disorders, Psychology, Pathological--Treatment--Handbooks, manuals, etc, Anhedonia--Handbooks, manuals, etc
- Abstract
This is the first comprehensive two-volume collection on anhedonia, a disorder that played an important role in psychopathology theories at the beginning of the twentieth century. Anhedonia is a condition in which the capacity of pleasure is partially or completely lost, and it refers to both a personality trait, and a “state symptom” in various neuropsychiatric and physical disorders. It has a putative neural substrate, originating in the dopaminergic mesolimbic and mesocortical reward circuit. Over the past three decades cognitive psychology and behavioral neuroscience have expanded our understanding of anhedonia and other reward-related processes. The aim of this new two-volume collection on anhedonia is to highlight the contributions of eminent scientists in this field as well as to provide readers with comprehensive accounts of recent developments as perceived by the authors. This monograph is divided into five parts. Volume I contains parts one and two (Conceptual Issues andNeurobiological Advances) including 14 chapters that serve as an introduction and overview of conceptual issues. Volume II contains three parts (Anhedonia in Psychotic Disorders, Anhedonia in Mood and Personality Disorders, and Anhedonia in Neurological and Physical Disorders) including 15 chapters that provide an overview of the construct, measurement of anhedonia in schizophrenia spectrum disorders, hedonic capacity and related factors in schizophrenia and schizoaffective disorder, anhedonia as an indicator of genetic liability for schizophrenia, and as a trait marker for depression, the role of an anhedonia in trauma-related disorders, anorexia nervosa, stress-induced eating disorders, schizotypal traits and risk of suicide. This book will be of interest to a broad spectrum of readers including psychiatrists, psychologists, neurologists, neuroscientists, endocrinologists, pharmacologists, general practitioners, geriatricians, graduate students, and health care providers in the fields of mental health.
- Published
- 2014
18. Anhedonia: A Comprehensive Handbook Volume I : Conceptual Issues And Neurobiological Advances
- Author
-
Michael S. Ritsner and Michael S. Ritsner
- Subjects
- Social psychology, Anhedonia--Handbooks, manuals, etc, Psychology, Pathological--Treatment--Handbooks, manuals, etc
- Abstract
This is the first comprehensive two-volume collection on anhedonia, a disorder that played an important role in psychopathology theories at the beginning of the twentieth century. Anhedonia is a condition in which the capacity of pleasure is partially or completely lost, and it refers to both a personality trait, and a “state symptom” in various neuropsychiatric and physical disorders. It has a putative neural substrate, originating in the dopaminergic mesolimbic and mesocortical reward circuit. Over the past three decades cognitive psychology and behavioral neuroscience have expanded our understanding of anhedonia and other reward-related processes. The aim of this new two-volume collection on anhedonia is to highlight the contributions of eminent scientists in this field as well as to provide readers with comprehensive accounts of recent developments as perceived by the authors. This monograph is divided into five parts. Volume I contains parts one and two (Conceptual Issues andNeurobiological Advances) including 14 chapters that serve as an introduction and overview of conceptual issues. Volume II contains three parts (Anhedonia in Psychotic Disorders, Anhedonia in Mood and Personality Disorders, and Anhedonia in Neurological and Physical Disorders) including 15 chapters that provide an overview of the construct, measurement of anhedonia in schizophrenia spectrum disorders, hedonic capacity and related factors in schizophrenia and schizoaffective disorder, anhedonia as an indicator of genetic liability for schizophrenia, and as a trait marker for depression, the role of an anhedonia in trauma-related disorders, anorexia nervosa, stress-induced eating disorders, schizotypal traits and risk of suicide. This book will be of interest to a broad spectrum of readers including psychiatrists, psychologists, neurologists, neuroscientists, endocrinologists, pharmacologists, general practitioners, geriatricians, graduate students, and health care providers in the fields of mental health.
- Published
- 2014
19. Bexarotene as Add-On to Antipsychotic Treatment in Schizophrenia Patients
- Author
-
Chanoch Miodownik, Michael S. Ritsner, Tatyana Shleifer, Anatoly Gibel, Vladimir Lerner, Ann B. Goodman, and Ekateryna Kovalyonok
- Subjects
Adult ,Male ,medicine.medical_specialty ,Tetrahydronaphthalenes ,Pilot Projects ,Akathisia ,Extrapyramidal symptoms ,Rating scale ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Psychiatry ,Pharmacology ,Bexarotene ,Dose-Response Relationship, Drug ,Middle Aged ,medicine.disease ,Clinical trial ,Mood ,Schizophrenia ,Chronic Disease ,Female ,Neurology (clinical) ,Abnormal Involuntary Movement Scale ,medicine.symptom ,Psychology ,Antipsychotic Agents ,medicine.drug - Abstract
Objectives:Bexarotene is a synthetic retinoid used for treat-ment of neoplastic or dermatologic disorders.Based on the retinoid dysregulation hypothesis, itwas hypothesized that bexarotene augmentationwould have a beneficial effect in the antipsychotictreatment of schizophrenia patients. This study isthe first to investigate the safety and efficacy ofadd-on oral bexarotene to ongoing antipsychotictreatment in chronic schizophrenia patientswho were stabilized on regular antipsychotictreatment.Methods:A 6-week open label trial was conducted in 2mental health centers from October 2005 toOctober 2006. Twenty-five patients with chronicschizophrenia received a low dose of bexarotene(75 mg/d) augmentation. Mental condition andlaboratory tests were assessed at baseline and afterweeks 2, 4, and 6 of the study. The primaryoutcome measure was change from baseline in 4symptom scales: the Positive and Negative Symp-tom Scale , Extrapyramidal Symptom Rating Scale,Abnormal Involuntary Movement Scale, andBarnes Akathisia Scale. Blood cell count, liver andthyroid functions, cholesterol, and triglyceriderates were followed.Results:Significant improvement from baseline to end-point was observed on total Positive and NegativeSymptom Scale score (P = 0.022), general psycho-pathology (P = 0.024), positive (P = 0.012), and thedysphoric mood (P = 0.028) factor scores. Further-more, a trend to a diminishing ExtrapyramidalSymptom Rating Scale score (P = 0.053) was found.Bexarotene was found to be a safe medication asmeasured by all laboratory parameters with theexception of increased total cholesterol serumlevel.Conclusions:This short-term pilot study supports bexarotene asa potential valuable adjunct in management ofschizophrenia. Low doses of bexarotene were welltolerated. A double-blind controlled study shouldbe performed to replicate these preliminary pos-itive results.Key Words: treatment-resistant schizophrenia,retinoids, bexarotene, negative symptoms
- Published
- 2008
20. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: A 12-month, open-label, flexible-dose, naturalistic observational trial
- Author
-
Anatoly Gibel, Vladimir Yorkov, Yael Ratner, and Michael S. Ritsner
- Subjects
Adult ,Male ,medicine.medical_specialty ,Global Assessment of Functioning ,Piperazines ,Internal medicine ,medicine ,Humans ,Ziprasidone ,Psychiatry ,Adverse effect ,Biological Psychiatry ,Psychiatric Status Rating Scales ,Pharmacology ,Positive and Negative Syndrome Scale ,Body Weight ,Middle Aged ,medicine.disease ,Discontinuation ,Thiazoles ,Tolerability ,Schizophrenia ,Chronic Disease ,Clinical Global Impression ,Female ,Psychology ,Antipsychotic Agents ,medicine.drug - Abstract
Objective This is a first report from a long-term study aimed to evaluate efficacy, safety, tolerability, cognitive functioning, and quality of life outcomes during ziprasidone treatment of chronic schizophrenia patients in the “real-world”. Method Seventy clinically unstable schizophrenia patients with persistent symptoms or troublesome side effects were assigned to a 12-month, open-label, flexible-dose (40–160 mg/day), large-scale, naturalistic trial. Outcome measures were taken at baseline, 6, and 12 months, and included the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression (CGI-S) scale, the Global Assessment of Functioning Scale (GAF) scores, treatment-emergent adverse events, body weight, and drug attitude. Results Thirty-two patients fully completed the study protocol. A discontinuation of treatment for any cause occurred in 54.3% of patients; the mean time until discontinuation was 4.4 ± 2.7 months. A discontinuation due to lack of clinical efficacy was more predominantly linked to patient perception (25.7%) than to physicians' conclusions alone (8.6%), adverse events (11.4%), and other reasons (8.6%). After controlling daily dose of ziprasidone, concomitant medications and sex, ANCOVA revealed improvement in PANSS factors, and global functioning among patients who had completed the study. Improvement in PANSS and GAF dimensions was evident at a 6-month visit, and it continued until the endpoint. When a cutoff of 20% improvement of PANSS total scores was used, the response rate among completers was 43.8%. Most common side effects were: fatigue, sleep disturbances, and headache. Ziprasidone did not appear to be linked to weight gain. Conclusion This study suggests that ziprasidone may be beneficial for long-term treatment of schizophrenia patients in terms of severity of symptoms, and general functioning. Ziprasidone is well tolerated during the long-term treatment of chronic schizophrenia patients undergoing usual care.
- Published
- 2007
21. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: A 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care
- Author
-
Peter Soifer, Vladimir Yorkov, Anatoly Gibel, Michael S. Ritsner, and Yael Ratner
- Subjects
Adult ,Male ,medicine.medical_specialty ,Side effect ,Piperazines ,Quality of life ,Surveys and Questionnaires ,medicine ,Humans ,Ziprasidone ,Psychiatry ,Biological Psychiatry ,Psychiatric Status Rating Scales ,Pharmacology ,Analysis of Variance ,Middle Aged ,medicine.disease ,Antiparkinson drug ,Thiazoles ,Distress ,Mood ,Schizophrenia ,Chronic Disease ,Quality of Life ,Physical therapy ,Female ,Schizophrenic Psychology ,Observational study ,Psychology ,Antipsychotic Agents ,medicine.drug - Abstract
Objective Health related quality of life (HRQL) has become an important outcome measure in the treatment of psychiatric disorders. This long-term observational study examined ziprasidone-induced improvement in satisfaction with HRQL in schizophrenia patients treated under real-world conditions. Method Seventy schizophrenia patients with persistent symptoms or troublesome side effects were assigned to a 12-month, open-label, flexible-dose (40–160 mg/d), large-scale, naturalistic trial. Outcome measures were taken at baseline, 6, and 12 months, and included the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), severity of symptoms, distress, and side effects. Results Thirty-two patients fully completed the study protocol. Patients reported poorer general HRQL compared with healthy subjects. At the end of the study, significant improvement in general activity, and satisfaction with life was observed. The effect sizes for these changes were moderate (0.55, and 0.72, respectively). After Bonferroni correction for multiple comparisons improvement in satisfaction with general activity remained significant. No significant changes were noted in other Q-LES-Q dimensions. Improvement in general activity was associated with a reduction in the severity of symptoms and emotional distress, but was unrelated to the ziprasidone daily dose, side effect scores, and concomitantly prescribed antidepressants, anxiolytics, mood stabilizers, or antiparkinson drugs. Conclusion This study indicates that ziprasidone treatment resulted in the improvement of the satisfaction with general activity that tended to increase over time, from month 6 onwards. This effect was associated with reduction in the severity of clinical symptoms, and emotional distress.
- Published
- 2007
22. Predicting quality of life impairment in chronic schizophrenia from cognitive variables
- Author
-
Michael S. Ritsner
- Subjects
Adult ,Male ,Self-Assessment ,medicine.medical_specialty ,Adolescent ,Models, Psychological ,Neuropsychological Tests ,Severity of Illness Index ,Cognition ,Quality of life ,Sickness Impact Profile ,medicine ,Humans ,Cognitive skill ,Israel ,Psychiatry ,Motor skill ,Psychiatric Status Rating Scales ,medicine.diagnostic_test ,Public Health, Environmental and Occupational Health ,Neuropsychological test ,Middle Aged ,Prognosis ,Executive functions ,medicine.disease ,Schizophrenia ,Cognitive remediation therapy ,Regression Analysis ,Female ,Schizophrenic Psychology ,Cognition Disorders ,Psychology - Abstract
Background The aim of this study was to see whether and how cognition deficit predicts quality of life impairments in schizophrenia patients. Method The Computerized Cambridge Automated Neuropsychological Test Battery, the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) and the Quality of Life Scale (QLS) were used to assess 62 patients with chronic schizophrenia. Step-wise multiple regression analysis was used in order to determine cognitive variables that would predict the scores of each Q-LES-Q and QLS domain scores. Results Regression analysis revealed a significant association of the cognitive deficits with both general and domain-specific quality of life impairment measured with Q-LES-Q and QLS. Deficits in executive functions, visual sustained attention, memory and motor skills have been found to be valid predictors both before and after controlling for the severity of symptoms, emotional distress, side effects, age, education, and illness duration. Conclusions This study suggests that deficits in executive functioning, attention, memory and motor skills substantially contributes to predicting impairments across a wide range of HRQL domains, and, consequently, to quality of life appraisal in schizophrenia. Cognitive predictors cannot be attributed to illness-related and background variables. It can be concluded that, when aiming at the improvement of quality of life in schizophrenia patients, cognitive functioning should be targeted.
- Published
- 2007
23. Predicting domain-specific insight of schizophrenia patients from symptomatology, multiple neurocognitive functions, and personality related traits
- Author
-
Haya Blumenkrantz and Michael S. Ritsner
- Subjects
Adult ,Male ,Coping (psychology) ,Adolescent ,media_common.quotation_subject ,Neuropsychological Tests ,Personality Disorders ,Severity of Illness Index ,Perceptual Disorders ,Surveys and Questionnaires ,Adaptation, Psychological ,Humans ,Personality ,Attention ,Prospective Studies ,Big Five personality traits ,Temperament ,Biological Psychiatry ,Aged ,media_common ,Positive and Negative Syndrome Scale ,Novelty seeking ,Brain ,Awareness ,Middle Aged ,Self Concept ,Self Efficacy ,Diagnostic and Statistical Manual of Mental Disorders ,Affect ,Psychiatry and Mental health ,Reward dependence ,Schizophrenia ,Visual Perception ,Female ,Psychomotor Disorders ,Cognition Disorders ,Psychology ,Attitude to Health ,Neurocognitive ,Psychopathology ,Clinical psychology - Abstract
This study examines the contribution of various neurocognitive functions, clinical characteristics, and personality traits to the prediction of three insight dimensions. Clinically stable schizophrenia patients (n=107) residing in the community were evaluated using the Positive and Negative Syndrome Scale, the Scale for the Assessment of Unawareness of Mental Disorder, and a comprehensive battery of instruments to measure personality related variables and neurocognitive functioning. Step-wise multivariate regression analysis indicates significant association of variability in insight dimensions with neurocognitive functioning (20-41%), personality related traits (8-18% temperament factors, 4-7% self-constructs, 10-14% coping styles), severity of symptoms (about 7%), illness duration (6%), and education (about 5%). Poor insight was attributed to impairment in visual and movement skills, sustained attention, executive functions, intensity of autistic preoccupations and positive symptoms, as well as increased novelty seeking behavior, task and emotion oriented coping styles, better self-esteem, self-efficacy, and higher education. Better awareness was related to better performance of neurocognitive tasks, reward dependence behavior, avoidant coping style, and longer illness duration. Aside from common indicators for the various insight dimensions, we defined specific indicators for each insight dimension. Thus, insight dimensions in schizophrenia patients residing in the community were attributed to neurocognitive and personality related factors rather than to psychopathological symptoms. The findings enable better understanding of the multifactorial nature of insight and highlight targets for more effective intervention and rehabilitation.
- Published
- 2007
24. Add-On Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- Author
-
Yael Ratner, Michael S. Ritsner, and Adasa Kardashev
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Placebo-controlled study ,Schizoaffective disorder ,Anxiety ,Placebo ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Glutamates ,Internal medicine ,mental disorders ,medicine ,Humans ,Prodrugs ,Antipsychotic ,Psychiatry ,Scale for the Assessment of Negative Symptoms ,Psychiatric Status Rating Scales ,Positive and Negative Syndrome Scale ,Drug Synergism ,General Medicine ,medicine.disease ,030227 psychiatry ,Diagnostic and Statistical Manual of Mental Disorders ,Psychiatry and Mental health ,Treatment Outcome ,Schizophrenia ,Pregnenolone ,Drug Therapy, Combination ,Female ,Schizophrenic Psychology ,medicine.symptom ,Drug Monitoring ,Psychology ,030217 neurology & neurosurgery ,Antipsychotic Agents - Abstract
Pregnenolone (PREG) and L-theanine (LT) have shown ameliorative effects on various schizophrenia symptoms. This is the first study to evaluate the efficacy and safety of augmentation of antipsychotic treatment among patients with chronic schizophrenia or schizoaffective disorder with PREG-LT.Double-blind, placebo-controlled trial of PREG-LT or placebo augmentation was conducted for eight weeks with 40 chronic DSM-IV schizophrenia and schizoaffective disorder patients with suboptimal response to antipsychotics. Oral PREG (50 mg/day) with LT (400 mg/day) or placebo were added to a stable regimen of antipsychotic medication from March 2011 to October 2013. The participants were rated using the Scale for the Assessment of Negative Symptoms (SANS), the Hamilton Scale for Anxiety (HAM-A), and the Positive and Negative Syndrome Scale (PANSS) scales bi-weekly. The decrease of SANS and HAM-A scores were the co-primary outcomes. Secondary outcomes included assessments of general functioning and side effects.Negative symptoms such as blunted affect, alogia, and anhedonia (SANS) were found to be significantly improved with moderate effect sizes among patients who received PREG-LT, in comparison with the placebo group. Add-on PREG-LT also significantly associated with a reduction of anxiety scores such as anxious mood, tension, and cardiovascular symptoms (HAM-A), and elevation of general functioning (GAF). Positive symptoms, antipsychotic agents, concomitant drugs, and illness duration did not associate significantly with effect of PREG-LT augmentation. PREG-LT was well-tolerated.Pregnenolone with L-theanine augmentation may offer a new therapeutic strategy for treatment of negative and anxiety symptoms in schizophrenia and schizoaffective disorder. Further studies are warranted.clinicaltrials.gov Identifier: NCT01831986.
- Published
- 2015
25. The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers
- Author
-
Michael S. Ritsner and Anatoly Gibel
- Subjects
Adult ,Olanzapine ,medicine.medical_specialty ,Adolescent ,medicine.drug_class ,medicine.medical_treatment ,Benzodiazepines ,Predictive Value of Tests ,Outpatients ,medicine ,Humans ,Antipsychotic ,Psychiatry ,Biological Psychiatry ,Pharmacology ,Risperidone ,Positive and Negative Syndrome Scale ,Patient Selection ,Confounding Factors, Epidemiologic ,Mood stabilizer ,Middle Aged ,medicine.disease ,Affect ,Treatment Outcome ,Mood ,Tolerability ,Schizophrenia ,Quality of Life ,Schizophrenic Psychology ,Psychology ,Antipsychotic Agents ,Follow-Up Studies ,medicine.drug - Abstract
Objective This study examined specific predictors of the efficacy of risperidone (RP), olanzapine (OL) and first-generation antipsychotic agents (FGAs), the role of confounding factors, and concomitant agents such as antidepressants, anxiolytics, and mood stabilizers in the treatment of health related quality of life (HRQL) impairment of schizophrenia patients. Method This was a community-based, open label, parallel group naturalistic study of 124 schizophrenia outpatients who received either RP, OL, FGA, or combined agents (CA). Evaluations were performed at baseline and 12 months later. They included the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), the Positive and Negative Syndrome Scale (PANSS), the Distress Scale for Adverse Symptoms, and inventories for the assessment of distress severity, subjective tolerability, and self-efficacy. Results OL was found to be superior to RP, FGAs and CA in terms of quality of life. FGAs revealed greater therapeutic benefit than RP, which was more beneficial than combined therapy. Improvement in Q-LES-Q was revealed in patients who received antidepressants and anxiolytics, but not mood stabilizers, or anti-Parkinson drugs. This effect was independent of treatment groups and gender. Regression models revealed that changes in emotional distress and side effects were common predictors for HRQL changes across treatment groups. Specific predictors of HRQL efficacy included self-efficacy for OL, negative and positive symptoms for RP, dysphoric mood and positive symptoms, daily doses and self-efficacy for FGA treated patients. Conclusion These findings suggest that OL is beneficial in the treatment of HRQL impairment in schizophrenia compared with RP, FGAs and CA. Special attention should be paid to specific predictors of HRQL efficacy for each antipsychotic agent, and to concomitant treatment with antidepressants and anxiolytics.
- Published
- 2006
26. Improvement of Sustained Attention and Visual and Movement Skills, but Not Clinical Symptoms, After Dehydroepiandrosterone Augmentation in Schizophrenia
- Author
-
Anatoly Gibel, Rael D. Strous, Michael S. Ritsner, German Tsinovoy, and Yael Ratner
- Subjects
Adult ,Male ,endocrine system ,medicine.medical_specialty ,Randomization ,medicine.medical_treatment ,Placebo ,law.invention ,Double-Blind Method ,Randomized controlled trial ,Management of schizophrenia ,Memory ,law ,Internal medicine ,polycyclic compounds ,medicine ,Humans ,Attention ,Pharmacology (medical) ,Adverse effect ,Antipsychotic ,Psychiatry ,Problem Solving ,Psychiatric Status Rating Scales ,Cross-Over Studies ,Dehydroepiandrosterone ,Middle Aged ,medicine.disease ,Crossover study ,Psychiatry and Mental health ,Treatment Outcome ,Schizophrenia ,Visual Perception ,Drug Therapy, Combination ,Female ,Schizophrenic Psychology ,Psychology ,human activities ,Psychomotor Performance ,hormones, hormone substitutes, and hormone antagonists ,Antipsychotic Agents - Abstract
Background: Dehydroepiandrosterone (DHEA) augmentation has been reported, in a preliminary fashion, to be useful in the management of schizophrenia symptoms and side effects. In this study, the intention was to investigate the efficacy and safety of DHEA administration to ongoing antipsychotic medication in a multicenter, 12-week, double-blind, randomized, placebo-controlled, crossover trial. Methods: Fifty-five of 62 inpatients and outpatients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis of schizophrenia completed the trial. Patients were randomly allocated to 2 treatment groups receiving either DHEA (200 mg/d) or placebo for 6 weeks with the crossover between DHEA and placebo occurring after 6 weeks. Patients continued to receive their regular antipsychotic medication for the duration of the study. Results: Compared with placebo, DHEA administration did not produce significant improvement in clinical symptoms, side effects, and quality-of-life scores. However, 6 weeks of DHEA administration (but not placebo) was associated with a significant improvement in Positive and Negative Symptom Scale ratings compared with baseline. Furthermore, 6 weeks of DHEA treatment was associated with significant improvement in cognitive functions of visual sustained attention and visual and movement skills compared with placebo conditions. The DHEA augmentation was associated with elevations of serum concentrations of both DHEA and its sulfate ester. The DHEA treatment was well tolerated without any serious adverse effects. Conclusion: This short-term study does not support DHEA's value as an effective adjunct in the treatment of symptoms, side effects, and quality-of-life impairment in schizophrenia, while suggesting that DHEA improves sustained attention and visual and movement skills. A long-term, large-scale study with a broader dose range is warranted to further investigate DHEA's role in the management of schizophrenia.
- Published
- 2006
27. The Long-Term Changes in Coping Strategies in Schizophrenia
- Author
-
Michael S. Ritsner and Yael Ratner
- Subjects
Adult ,Male ,Coping (psychology) ,Psychosis ,medicine.medical_specialty ,Time Factors ,Adolescent ,Personality Inventory ,medicine.medical_treatment ,Emotions ,Severity of Illness Index ,Life Change Events ,Surveys and Questionnaires ,Adaptation, Psychological ,Severity of illness ,medicine ,Humans ,Longitudinal Studies ,Prospective Studies ,Psychiatry ,Psychiatric Status Rating Scales ,Self-efficacy ,Rehabilitation ,Middle Aged ,medicine.disease ,Self Efficacy ,Hospitalization ,Psychiatry and Mental health ,Schizophrenia ,Female ,Schizophrenic Psychology ,Personality Assessment Inventory ,Psychology ,Social Adjustment ,Psychosocial ,Follow-Up Studies ,Clinical psychology ,Psychopathology - Abstract
This prospective study aimed to define the long-term changes in coping strategies used by schizophrenia patients and their relation to clinical and psychosocial factors. The Coping Inventory for Stressful Situations, psychiatric scales, and self-report questionnaires were administered to 148 schizophrenia patients at admission and 16 months thereafter. Based on trends of individual coping patterns to show change over time, four temporal coping types were distinguished: stable favorable and unfavorable, and becoming favorable and unfavorable. We found that coping patterns of 62.2% of patients remained stable over time, became unfavorable among 19.6% of patients, and became favorable among 18.2% of patients. Each temporal coping type is associated with a specific pattern of changes in clinical and psychosocial variables. The findings underscore the clinical relevance of temporal coping types and corroborate the appropriateness of focusing on aspects of coping behavior in treatment and rehabilitation of schizophrenia patients.
- Published
- 2006
28. Determinants of Changes in Perceived Quality of Life in the Course of Schizophrenia
- Author
-
Anatoly Gibel, Michael S. Ritsner, and Yael Ratner
- Subjects
Adult ,Male ,medicine.medical_specialty ,Coping (psychology) ,Adolescent ,Social support ,Surveys and Questionnaires ,medicine ,Humans ,Expressed emotion ,Longitudinal Studies ,Israel ,Psychiatry ,Public health ,Public Health, Environmental and Occupational Health ,Middle Aged ,Mental health ,humanities ,Distress ,Quality of Life ,Schizophrenia ,Female ,Psychology ,Psychosocial ,Psychopathology ,Clinical psychology - Abstract
This study aimed to identify factors that influence changes in satisfaction with quality of life (QOL) of schizophrenia patients. Baseline and follow up data for 148 schizophrenia patients were obtained at hospital admission and 16 months later. Relationships between changes over time in the general QOL index, and various factors were investigated using factor, multiple regression, and partial correlation analyses. Findings indicate that baseline levels of activation symptoms, emotional distress, task oriented coping, self-esteem and friend support together explain 41% of the variability in the general QOL index 16 months later. Changes in the general QOL of schizophrenia patients over time is associated with anergia, and paranoid symptoms, emotional distress, side effects, self-esteem, emotion and avoidance related coping styles, expressed emotion, and other social support. Determinants of change in QOL of patients were different being in hospital or out of hospital in the real world. No significant association of age, education, and follow up duration, with general QOL. Based on obtained data three types of overlapping factors were defined: (1) distressing, and protective; (2) primary and secondary; and (3) factors that remained constant or changed over time. Presented data are discussed within the framework of the Distress/Protection model of QOL. The conceptualization of three types of factors influencing QOL outcomes in this model demonstrates their predictive value, and may assist investigators and mental health workers in the interpretation of QOL data that may be used to improve patients' QOL outcomes.
- Published
- 2006
29. Alterations in DHEA metabolism in schizophrenia: Two-month case-control study
- Author
-
Anatoli Gibel, Abraham Weizman, Michael S. Ritsner, Edward Ram, and Rachel Maayan
- Subjects
Adult ,Male ,Aging ,Dyskinesia, Drug-Induced ,endocrine system ,medicine.medical_specialty ,Neuroactive steroid ,Psychometrics ,medicine.medical_treatment ,Dehydroepiandrosterone ,Anxiety ,Internal medicine ,mental disorders ,polycyclic compounds ,Humans ,Medicine ,Testosterone ,Pharmacology (medical) ,Androstenedione ,skin and connective tissue diseases ,Antipsychotic ,Progesterone ,Biological Psychiatry ,Psychiatric Status Rating Scales ,Pharmacology ,Dehydroepiandrosterone Sulfate ,business.industry ,Middle Aged ,medicine.disease ,Prolactin ,Psychiatry and Mental health ,Endocrinology ,Neurology ,Schizophrenia ,Case-Control Studies ,Schizophrenic Psychology ,Neurology (clinical) ,business ,hormones, hormone substitutes, and hormone antagonists ,Antipsychotic Agents ,Hormone - Abstract
Objective: The goals of this study were to determine whether alterations in serum dehydroepiandrosterone (DHEA), its sulfated conjugate (DHEAS), androstenedione, testosterone, and progesterone concentrations occur in schizophrenia patients compared with healthy controls over two months, and their associations with psychopathology, emotional distress, and antipsychotic treatment. Method: Serum hormones were repeatedly determined for 21 antipsychotic-treated male DSM-IV schizophrenia patients and 14 healthy controls. Observations were at four time points: upon entry into the study, and after 2, 4 and 8 weeks. Results: In schizophrenia patients compared with healthy controls serum concentration of DHEA and androstenedione found increased, but that of DHEAS decreased, while progesterone and testosterone showed normal levels. Schizophrenia patients were also characterized by elevated androstenedione / DHEAS molar ratios, and reduced DHEAS / DHEA and testosterone / androstenedione molar ratios compared with healthy controls. Concentrations and molar ratios of serum hormones did not significantly change during the study either among schizophrenia patients, or healthy controls. Among patients alterations in DHEA, DHEAS and androstenedione were associated with emotional distress, anxiety, dysphoric mood, positive and activation symptoms, serum prolactin levels, but were not related to age, antipsychotic agents, and extrapyramidal side effects. Conclusions: Alterations in DHEA metabolism in schizophrenia are attributed to the distress, anxiety, severity of symptoms, prolactin levels, and may represent a marker for impaired hormonal responses to stress. These findings should be considered when evaluating the discrepancies in DHEA studies in schizophrenia.
- Published
- 2006
30. The detection of neurocognitive decline in schizophrenia using the Mindstreams Computerized Cognitive Test Battery
- Author
-
Tzvi Dwolatzky, Michael S. Ritsner, Tatiana Dubinsky, and Haya Blumenkrantz
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Psychometrics ,Neuropsychological Tests ,Severity of Illness Index ,Neuropsychology ,medicine ,Humans ,Diagnosis, Computer-Assisted ,Psychiatry ,Biological Psychiatry ,Positive and Negative Syndrome Scale ,Cambridge Neuropsychological Test Automated Battery ,Brain ,Reproducibility of Results ,Cognition ,Middle Aged ,medicine.disease ,Cognitive test ,Psychiatry and Mental health ,Schizophrenia ,Female ,Cognition Disorders ,Psychology ,Neurocognitive ,Software ,Clinical psychology - Abstract
Background The Mindstreams Computerized Cognitive Test Battery (Mindstreams) is a standardized computer-based battery that was designed for widespread clinical and research use. The capability of Mindstreams to test cognitive impairment in schizophrenia has yet to be evaluated. The aim of the present study was to determine the ability of Mindstreams in detecting cognitive dysfunction in schizophrenia patients and to compare it to the Cambridge Neuropsychological Test Automated Battery (CANTAB). Method Fifty-five schizophrenia patients and 63 healthy subjects were enrolled in the study. The Positive and Negative Syndrome Scale (PANSS) was used to quantify symptom severity. Neurocognitive functions were assessed using Mindstreams and CANTAB. Results The schizophrenia patients scored significantly more poorly than healthy subjects on all tests comprising the Mindstreams battery. Comparable tasks of the Mindstreams and CANTAB batteries significantly correlated on raw scores and the standardized cognitive indices. The Mindstreams executive function tasks had significant correlations with the PANSS negative, autistic preoccupation and activation cluster scores, and with global functioning. Two-week test–retest reliability correlations were all significant ( N = 17, p p Conclusions This study indicates that Mindstreams is reliable in assessing the cognitive function of patients with schizophrenia and may play a role in standardizing the cognitive assessment of these patients in clinical and research settings.
- Published
- 2006
31. Familiality in a five-factor model of schizophrenia psychopathology: Findings from a 16-month follow-up study
- Author
-
Anatoly Gibel, Ronit Weizman, Michael S. Ritsner, and Yael Ratner
- Subjects
Adult ,Male ,Psychosis ,medicine.medical_specialty ,Time Factors ,Adolescent ,Severity of Illness Index ,behavioral disciplines and activities ,Surveys and Questionnaires ,mental disorders ,Severity of illness ,Brief Psychiatric Rating Scale ,medicine ,Humans ,Family history ,Psychiatry ,Biological Psychiatry ,Positive and Negative Syndrome Scale ,Middle Aged ,medicine.disease ,Diagnostic and Statistical Manual of Mental Disorders ,Psychiatry and Mental health ,Schizophrenia ,Female ,Schizophrenic Psychology ,Age of onset ,Factor Analysis, Statistical ,Psychology ,Follow-Up Studies ,Psychopathology - Abstract
We sought to examine stability associations between family history and variability of schizophrenia symptoms repeatedly examined during a naturalistic follow-up study. The Positive and Negative Syndrome Scale, the Insight and Treatment Attitudes Questionnaire, and the Abnormal Involuntary Movement Scale were administered to 69 patients with familial and 79 patients with sporadic schizophrenia, at hospital admission and at stabilization stage (about 16 months later). Analysis of covariance was applied to identify the association of symptom factors with familiality of schizophrenia. We found that schizophrenia patients with positive family histories had significantly higher dysphoric, activation and negative factors. However, familiality of activation and negative factors were dependent on additional variables such as age of onset (both factors), baseline ratings, insight, and side effects (negative factor). No significant association of family history with intensity of positive and autistic preoccupation factors was found. Familial schizophrenia is characterized by higher severity of dysphoric mood factors that may represent impaired emotional reactivity. It is suggested that dysphoric mood may be a useful phenotype for molecular genetic studies of schizophrenia with positive family history.
- Published
- 2005
32. Validity of an abbreviated Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective,and mood disorder patients
- Author
-
Anatoly Gibel, Rena Kurs, Jean Endicott, Michael S. Ritsner, and Yael Ratner
- Subjects
Adult ,Male ,medicine.medical_specialty ,Psychometrics ,Affect (psychology) ,behavioral disciplines and activities ,Social support ,Quality of life (healthcare) ,Rating scale ,Sickness Impact Profile ,Surveys and Questionnaires ,otorhinolaryngologic diseases ,medicine ,Humans ,Psychiatry ,Mood Disorders ,Public Health, Environmental and Occupational Health ,medicine.disease ,Affect ,Mood ,Psychotic Disorders ,Mood disorders ,Patient Satisfaction ,Schizophrenia ,Quality of Life ,Female ,Psychology ,Clinical psychology ,Psychopathology - Abstract
We sought to identify a core subset of Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) items that maintains the validity and psychometric properties of the basic version. A parsimonious subset of items from the Q-LES-Q that can accurately predict the basic Q-LES-Q domain mean scores was sought and evaluated in 339 inpatients meeting DSM-IV criteria for schizophrenia, schizoaffective, and mood disorders. Three additional data sets were used for validation. Assessments included Q-LES-Q, Quality of Life Scale, Lancashire Quality of Life Profile, rating scales for psychopathology, medication side effects, and self-reported emotional distress, self-esteem, self-efficacy, and social support. We found that 18-items predicted basic Q-LES-Q domains (physical health, subjective feelings, leisure time activities, social relationships) and general index scores with high accuracy. Q-LES-Q-18 showed high reliability, validity, and stability of test-retest ratings. Thus, Q-LES-Q-18, a brief, self-administered questionnaire may aid in monitoring quality of life outcomes of schizophrenia, schizoaffective, and mood disorder patients.
- Published
- 2005
33. Cortisol/Dehydroepiandrosterone Ratio and Responses to Antipsychotic Treatment in Schizophrenia
- Author
-
Rachel Maayan, Michael S. Ritsner, Ilan Modai, Yael Ratner, Hassan Biadsy, Edward Ram, Abraham Weizman, and Anatoly Gibel
- Subjects
Adult ,Male ,endocrine system ,Psychosis ,medicine.medical_specialty ,Time Factors ,Hydrocortisone ,Exacerbation ,medicine.medical_treatment ,Drug Resistance ,Radioimmunoassay ,Dehydroepiandrosterone ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Antipsychotic ,Prospective cohort study ,Pharmacology ,Analysis of Variance ,Middle Aged ,medicine.disease ,Psychiatry and Mental health ,Endocrinology ,Schizophrenia ,Female ,Psychology ,hormones, hormone substitutes, and hormone antagonists ,Glucocorticoid ,Antipsychotic Agents ,medicine.drug - Abstract
Dehydroepiandrosterone (DHEA) or their sulfate conjugate (DHEAS) (together abbreviated DHEA(S)) exert multiple effects in the central nervous system, and may be involved in the pathophysiological processes in schizophrenia. This prospective study aimed to investigate whether serum cortisol/DHEA(S) molar ratios are associated with response to antipsychotic treatment during the exacerbation of schizophrenia. Serum DHEA(S) and cortisol were determined at baseline, and 2 and 4 weeks later for 43 medicated schizophrenia inpatients with acute exacerbation. The patients were treated with stable doses of antipsychotic agents up to 2 weeks prior to entering the study and for the 4-week duration of the study after which they were classified as either responders or nonresponders to treatment. Findings suggest that responders had significantly higher serum cortisol levels and cortisol/DHEA(S) ratios compared with nonresponders. These differences remained significant at three time points controlling for gender, age, severity of symptoms and emotional distress, benzodiazepines, type or dosage of antipsychotic agents, and background variables. The logistic regression model shows advantages of both cortisol/DHEA(S) molar ratios vs serum cortisol and DHEA(S) concentrations for prediction of responsivity to antipsychotic treatment. No significant canonical correlations were observed between changes from baseline through end-of-study in hormonal values and severity of symptoms and emotional distress among responders and nonresponders. Thus, these data provide evidence that elevated serum cortisol and cortisol/DHEA(S) ratios may serve as markers of biological mechanisms that are involved in responsivity of schizophrenia patients to antipsychotic treatment.
- Published
- 2005
34. Longitudinal assessment of coping abilities at exacerbation and stabilization in schizophrenia
- Author
-
Michael S. Ritsner, Anatoly Gibel, Alexander M. Ponizovsky, Rael D. Strous, and Yael Ratner
- Subjects
Adult ,Male ,Psychosis ,Coping (psychology) ,medicine.medical_specialty ,Exacerbation ,lcsh:RC435-571 ,Life Change Events ,Social support ,Emotional distress ,Surveys and Questionnaires ,lcsh:Psychiatry ,Adaptation, Psychological ,medicine ,Humans ,Psychiatry ,Mood Disorders ,Avoidance coping ,Social Support ,Regression analysis ,medicine.disease ,Self Efficacy ,Psychiatry and Mental health ,Clinical Psychology ,Quality of Life ,Schizophrenia ,Regression Analysis ,Female ,Schizophrenic Psychology ,Psychology ,Follow-Up Studies ,Psychopathology ,Clinical psychology - Abstract
Background Coping strategies play an important role in one's ability to adapt to stressful life conditions such as schizophrenia. To better understand the nature of various coping mechanisms at various stages in schizophrenia, this study examined task-, emotion-, and avoidance-oriented coping strategies and explored associated clinical factors at exacerbation and stabilization phases of the illness. Method Patients with schizophrenia were examined twice (at exacerbation phase, N = 237 and at stabilization phase, N = 148) with the Coping Inventory for Stressful Situations, and standardized measures of psychopathology and emotional distress severity, side effects, insight, self-constructs, social support, and quality of life. Multiple regression analysis was performed with coping strategies as dependent variables at exacerbation and stabilization including analysis of any change during the 16-month follow-up period. Results Analysis indicated that emotion coping strategies were used more at exacerbation than at stabilization phase. Regression analysis demonstrated emotional distress to be a strong predictor of emotion-oriented coping, with self-efficacy and social support being the best predictors of task and avoidance coping strategies, respectively. Individual changes in these variables also appear to be important predictors for fluctuations of these coping strategies over time. Severity of symptoms accounted for 3.5% and 5.5% to 9% of the total variance of emotion- and task-oriented coping strategies, respectively. Conclusions Emotion, task, and avoidance coping strategies and their predictors are influenced and may vary over the course of schizophrenia illness. Experienced emotional distress, self-efficacy, and social support are the best predictors of coping strategies both at exacerbation and stabilization phases of illness.
- Published
- 2005
35. Is the G72/G30 locus associated with schizophrenia? single nucleotide polymorphisms, haplotypes, and gene expression analysis
- Author
-
Alina Cholostoy, Maya Ashkenazi, Yael Ratner, Edna Ben-Asher, Miryam Kaganovich, Michael S. Ritsner, Michael Korostishevsky, Ruth Navon, Ullrike Bening-Abu-Shach, Jeanne Bernstein, Dvir Dahary, and Doron Lancet
- Subjects
Adult ,Male ,Linkage disequilibrium ,Adolescent ,Population ,Gene Expression ,Prefrontal Cortex ,Locus (genetics) ,Single-nucleotide polymorphism ,Biology ,Polymorphism, Single Nucleotide ,Linkage Disequilibrium ,White People ,Gene Frequency ,Genetic linkage ,Humans ,Genetic Predisposition to Disease ,RNA, Messenger ,education ,Gene ,Biological Psychiatry ,Aged ,Genetics ,education.field_of_study ,Reverse Transcriptase Polymerase Chain Reaction ,Haplotype ,Intracellular Signaling Peptides and Proteins ,Proteins ,Middle Aged ,Ashkenazi jews ,Haplotypes ,Case-Control Studies ,Jews ,Postmortem Changes ,Schizophrenia ,Female ,Carrier Proteins - Abstract
Background The genes G72/G30 were recently implicated in schizophrenia in both Canadian and Russian populations. We hypothesized that 1) polymorphic changes in this gene region might be associated with schizophrenia in the Ashkenazi Jewish population and that 2) changes in G72/G30 gene expression might be expected in schizophrenic patients compared with control subjects. Methods Eleven single nucleotide polymorphisms (SNPs) encompassing the G72/G30 genes were typed in the genomic deoxyribonucleic acid (DNA) from 60 schizophrenic patients and 130 matched control subjects of Ashkenazi ethnic origin. Case–control comparisons were based on linkage disequilibrium (LD) and haplotype frequency estimations. Gene expression analysis of G72 and G30 was performed on 88 postmortem dorsolateral prefrontal cortex samples. Results Linkage disequilibrium analysis revealed two main SNP blocks. Haplotype analysis on block II, containing three SNPs external to the genes, demonstrated an association with schizophrenia. Gene expression analysis exhibited correlations between expression levels of the G72 and G30 genes, as well as a tendency toward overexpression of the G72 gene in schizophrenic brain samples of 44 schizophrenic patients compared with 44 control subjects. Conclusions It is likely that the G72/G30 region is involved in susceptibility to schizophrenia in the Ashkenazi population. The elevation in expression of the G72 gene coincides with the glutamatergic theory of schizophrenia.
- Published
- 2004
36. Aggregability of Red Blood Cells of Schizophrenia Patients With Negative Syndrome Is Selectively Enhanced
- Author
-
Gregory Barshtein, Yakov Nechamkin, Alexander M. Ponizovsky, Lev D. Bergelson, Michael S. Ritsner, and Saul Yedgar
- Subjects
Adult ,Erythrocyte Aggregation ,Male ,Psychosis ,medicine.medical_specialty ,Pathology ,Phospholipid ,Severity of Illness Index ,Erythrocyte aggregation ,Microcirculation ,Blood cell ,chemistry.chemical_compound ,Internal medicine ,medicine ,Humans ,Positive and Negative Syndrome Scale ,business.industry ,Reproducibility of Results ,medicine.disease ,Diagnostic and Statistical Manual of Mental Disorders ,Psychiatry and Mental health ,Red blood cell ,Endocrinology ,medicine.anatomical_structure ,chemistry ,Schizophrenia ,Cerebrovascular Circulation ,Female ,business - Abstract
Schizophrenia patients can be categorized into positive and negative syndromes (PS and NS) by the behavioral criteria of the Positive and Negative Syndrome Scale (PANSS), but these symptoms can also be evaluated as a continuous trait. Both types exhibit cerebral microcirculatory disorders, which are ameliorated by drug treatment in PS but not in NS patients. Red blood cell (RBC) aggregability plays a major role in the microcirculation. Previously reported changes in RBC membrane phospholipid composition indicate a difference in aggregability between RBCs of NS and PS patients. In this study the aggregability of PS RBCs and NS RBCs was analyzed using a computerized cell flow-properties analyzer, as a physiological marker of NS and PS. Results showed that while the aggregability of PS RBCs was normal, that of NS RBCs was markedly enhanced and strongly correlated with the NS score. The results exhibited stability and reproducibility over 1 to 8 weeks test-retest and were independent of gender, age at testing and onset of illness, fibrinogen levels, smoking, and current medication. NS RBCs have constitutively elevated aggregability, which can contribute to cerebral microcirculatory disorders and may be a biological marker for distinguishing between PS and NS in genetic studies of schizophrenia.
- Published
- 2004
37. Polypharmacy in Psychiatry Practice, Volume I : Multiple Medication Use Strategies
- Author
-
Michael S Ritsner and Michael S Ritsner
- Subjects
- Polypharmacy, Psychotropic drugs
- Abstract
Although monotherapy is generally recommended as the treatment of choice, treatment resistance of patients with psychosis, cognitive, mood and anxiety disorders represents a significant clinical problem. In this context, augmentation and combination strategies are commonly employed to address this problem. Although multiple medication use common in psychiatric practice, reasons, efficacy and safety for polypharmacy, and augmentative strategies have remained unclear. It remains unclear if there is an evidence base to support polypharmacy. Furthermore, excessive and inappropriate use of psychotropic medications has been recognized as a public health problem. This volume set is the first comprehensive, clinically oriented, reference on the multiple medication use to treat psychotic, cognitive, mood and anxiety disorders.
- Published
- 2013
38. Polypharmacy in Psychiatry Practice, Volume II : Use of Polypharmacy in the 'Real World'
- Author
-
Michael S Ritsner and Michael S Ritsner
- Subjects
- Polypharmacy, Psychotropic drugs
- Abstract
Although monotherapy is generally recommended as the treatment of choice, treatment resistance of patients with psychosis, cognitive, mood and anxiety disorders represents a significant clinical problem. In this context, augmentation and combination strategies are commonly employed to address this problem. Although multiple medication use common in psychiatric practice, reasons, efficacy and safety for polypharmacy, and augmentative strategies have remained unclear. It remains unclear if there is an evidence base to support polypharmacy. Furthermore, excessive and inappropriate use of psychotropic medications has been recognized as a public health problem. This volume is the first comprehensive, clinically oriented, reference on the multiple medication use to treat psychotic, cognitive, mood and anxiety disorders.
- Published
- 2013
39. The Attribution of Somatization in Schizophrenia Patients
- Author
-
Michael S. Ritsner
- Subjects
Adult ,Male ,Psychosis ,medicine.medical_specialty ,Emotions ,Population ,Schizoaffective disorder ,Risk Factors ,medicine ,Humans ,Expressed emotion ,Longitudinal Studies ,Bipolar disorder ,Somatoform Disorders ,Psychiatry ,education ,education.field_of_study ,Incidence ,Social Support ,medicine.disease ,Self Concept ,Psychiatry and Mental health ,Schizophrenia ,Regression Analysis ,Major depressive disorder ,Female ,Family Relations ,Psychology ,Somatization ,Stress, Psychological ,Antipsychotic Agents ,Psychopathology ,Clinical psychology - Abstract
Background Knowledge is limited concerning somatic symptoms that cannot be accounted for by detectable somatic illness among schizophrenia patients. This study aimed to explore the prevalence, correlates, and predictors of somatization among schizophrenia patients. Method Initial data on all consecutively admitted adult patients with DSM-IV schizophrenia, schizoaffective disorder, major depressive disorder, or bipolar disorder were collected between August 1998 and August 2000. Standardized measures of psychopathology, somatization, emotional distress, adverse effects, insight, and stress process-related (psychosocial) variables were administered to 237 schizophrenia patients at admission and at least 12 months thereafter (N = 148). Partial correlation and multiple regression analyses were performed. Results The frequency of somatization, defined as the presentation of 5 or more medically unexplained somatic symptoms (Somatic Symptom Index-5), among the inpatient population (27%) did not change significantly after at least 12 months (30%; p =.61). Regression analysis showed that somatization scores were best predicted by the combination of scores for emotional distress attributed to psychopathology and side effects, expressed emotion, and insight. This combined model explains at least 40% of the variance in somatization scores. Self-esteem and social support showed negative association with somatization scores. Somatization scores were not associated with gender, age, education, age at onset, observed severity of psychopathology, subtype and duration of illness, number of admissions and treatment settings, or type and dose of antipsychotic agents. Conclusions Somatization is a prevalent problem among schizophrenia patients and is associated with emotional distress attributed to psychopathology, side effects of antipsychotic agents, and family members' attitudes toward schizophrenia patients. This study suggests that insight, self-esteem, and social support may protect against somatization in schizophrenia patients.
- Published
- 2003
40. Decreased platelet peripheral-type benzodiazepine receptors in persistently violent schizophrenia patients
- Author
-
Ilan Modai, Moshe Gavish, Anatoly Gibel, German Tsinovoy, Svetlana Leschiner, Henry Silver, Michael S. Ritsner, and Abraham Weizman
- Subjects
Adult ,Blood Platelets ,Male ,Periodicity ,medicine.medical_specialty ,Psychosis ,PK-11195 ,Psychometrics ,medicine.drug_class ,Atypical antipsychotic ,Cell Count ,Hostility ,Violence ,Severity of Illness Index ,chemistry.chemical_compound ,Internal medicine ,mental disorders ,medicine ,Humans ,Psychiatry ,Biological Psychiatry ,Incidence ,Middle Aged ,Receptors, GABA-A ,medicine.disease ,Diagnostic and Statistical Manual of Mental Disorders ,Psychiatry and Mental health ,Distress ,chemistry ,Schizophrenia ,Chronic Disease ,Anxiety ,Female ,medicine.symptom ,Psychology ,Antipsychotic Agents ,Psychopathology - Abstract
Peripheral-type benzodiazepine receptors (PBR) have been shown to be sensitive to stressful conditions. This study aimed to explore a possible association of platelets PBR binding with aggressive behavior and homicidal history in schizophrenia patients. The authors compared [(3)H] PK 11195 binding to platelet membrane among 11 currently aggressive schizophrenia patients, 15 schizophrenia patients with homicidal history, 14 nonaggressive schizophrenia patients, and 15 healthy volunteers. Subjects were assessed for aggressive behavior, psychopathology, anxiety, anger, and emotional distress using standardized instruments. We found that currently aggressive patients had significantly lower (-30%) platelet PBR density (B(max)), and scored significantly higher on hostility, anxiety, state anger, and emotional distress compared to homicidal and nonaggressive schizophrenia patients and healthy controls. Predominance of positive or negative symptoms, homicidal or suicidal attempt history, emotional distress levels, and conventional or atypical antipsychotic therapy is not associated with the expression of platelet PBR binding sites. Significant negative correlations emerged between PBR density and scores for aggressive behavior, hostility and anxiety. Thus, decreased platelet PBR density in aggressive schizophrenia patients is associated with higher scores for overt aggression, hostility and anxiety, but independent of illness subtype, homicidal and suicidal attempt history, distress level and type of antipsychotic treatment.
- Published
- 2003
41. Satisfaction With Quality of Life Varies With Temperament Types of Patients With Schizophrenia
- Author
-
Herman Farkas, Michael S. Ritsner, and Anatoly Gibel
- Subjects
Adult ,Male ,medicine.medical_specialty ,media_common.quotation_subject ,Personal Satisfaction ,Tridimensional Personality Questionnaire ,Quality of life ,Surveys and Questionnaires ,medicine ,Humans ,Temperament ,Psychiatry ,media_common ,Analysis of Variance ,Novelty seeking ,Life satisfaction ,Middle Aged ,medicine.disease ,humanities ,Psychiatry and Mental health ,Distress ,Reward dependence ,Quality of Life ,Schizophrenia ,Regression Analysis ,Harm avoidance ,Female ,Schizophrenic Psychology ,Psychology - Abstract
We sought to explore the relationships of three temperament factors with domain-specific subjective quality of life (QOL) of patients with schizophrenia. Ninety patients with schizophrenia were evaluated using the Quality of Life Enjoyment and Life Satisfaction Questionnaire, the Tridimensional Personality Questionnaire, the Positive and Negative Syndromes Scale, the Distress Scale for Adverse Symptoms, the Insight and Treatment Attitudes Questionnaire, the Insight Self-Report Scale, and standardized questionnaires for self-reported emotional distress and stress process-related variables. Predictors of domain-specific QOL were identified using multiple regression techniques. Temperament factors explain 6% to 16% of variability in QOL domain scores among patients with schizophrenia after controlling for the remaining variables (emotional distress, social support, self-esteem, avoidance coping, age, side effects, and depression). We found that higher levels of novelty seeking are associated with better general QOL, physical health, and more positive subjective feelings, whereas higher levels of reward dependence are related to better satisfaction from social relationships. Higher levels of harm avoidance are associated with poorer satisfaction with general activities, and medication. Thus, temperament factors, as assessed by the Tridimensional Personality Questionnaire, substantially influence satisfaction with life quality in schizophrenia. Novelty seeking, reward dependence, and harm avoidance are associated with different domains of QOL.
- Published
- 2003
42. Predictors of Quality of Life in Major Psychoses
- Author
-
Evgeny Shinkarenko, Michael S. Ritsner, Yael Ratner, Anatoly Gibel, Rena Kurs, and Shmuel Hirschmann
- Subjects
Adult ,Affective Disorders, Psychotic ,Male ,medicine.medical_specialty ,Personality Inventory ,Health Status ,Personal Satisfaction ,Severity of Illness Index ,behavioral disciplines and activities ,Sex Factors ,Quality of life ,Adaptation, Psychological ,mental disorders ,medicine ,Humans ,Expressed emotion ,Longitudinal Studies ,Bipolar disorder ,Age of Onset ,Psychiatry ,Probability ,Psychiatric Status Rating Scales ,medicine.disease ,humanities ,Hospitalization ,Psychiatry and Mental health ,Distress ,Mood ,Psychotic Disorders ,Mood disorders ,Quality of Life ,Schizophrenia ,Regression Analysis ,Female ,Schizophrenic Psychology ,Psychology ,Somatization ,Follow-Up Studies ,Psychopathology ,Clinical psychology - Abstract
Background Improved quality of life (QOL) of patients suffering from major psychoses has become an important treatment goal. We sought to determine predictors of perceived QOL and to explore the changes that occur regarding QOL among individuals with schizophrenia as compared to patients with schizoaffective/mood disorders. Method In a naturalistic longitudinal design, 148 inpatients with schizophrenia and 51 inpatients with schizoaffective/mood disorders (DSM-IV) were tracked for 16 months (SD = 4.6 months). Subjects were assessed at 2 timepoints for psychopathology, stress process-related factors, and perceived QOL, as measured by the Quality of Life Enjoyment and Satisfaction Questionnaire. Predictors of fluctuations in QOL index scores during the follow-up period were identified using multiple regression techniques. Results We found that poor QOL is not a more severe problem for schizophrenia patients than for schizoaffective/mood disorder patients. Improved QOL of schizophrenia patients is associated with reduced paranoid and distress (obsessiveness, somatization) symptoms and increased self-efficacy and self-esteem ratings. Individual changes in QOL index scores among patients with schizoaffective/mood disorders are associated with changes in depression, sensitivity, expressed emotion, and task-oriented coping scores. Conclusion Predictors of changes in satisfaction with life quality over time among schizophrenia patients are distinct from those associated with schizoaffective/mood disorders. Changes in stress process-related factors, rather than psychopathology, predict change in perceived QOL and should be considered when evaluating QOL outcomes.
- Published
- 2003
43. [Untitled]
- Author
-
Alexander M. Ponizovsky, E. Bistrov, Ilan Modai, I. Timinsky, I Ben-Avi, and Michael S. Ritsner
- Subjects
Coping (psychology) ,medicine.medical_specialty ,Public health ,Public Health, Environmental and Occupational Health ,Health services research ,humanities ,Distress ,Quality of life ,Schizophrenic Psychology ,medicine ,Anxiety ,medicine.symptom ,Psychology ,Psychopathology ,Clinical psychology - Abstract
The question addressed in this paper is whether different coping styles mediate the relationship between psychopathology and related distress and the quality of life (QOL) among patients with schizophrenia. In a cross-sectional design, 161 schizophrenia inpatients were comprehensively evaluated with standardized measures of QOL, psychopathology, psychological distress and coping styles. Correlations and regression analyses were performed to examine the relationship among parameters and to estimate the mediating effect of coping styles on QOL in the framework of a distress/protection model. Life quality correlated positively with task- and avoidance-oriented coping styles and slightly negatively with emotion-oriented coping. Emotion-oriented coping mediated the relationship between the severity of activation, anxiety/depression symptoms, and QOL, while avoidance-oriented (distraction) coping was mediated between QOL and paranoid symptoms. Coping styles accounted for 25% of the variance in subjective QOL scores compared with 15% for psychological distress, and only 3% for clinical variables. The ability to cope with symptoms and associated distress substantially contributes to QOL appraisal in schizophrenia. Thus, different coping strategies may reduce the negative influence of specific symptoms and related distress on the subjective QOL of schizophrenia patients.
- Published
- 2003
44. Validación de la Escala Informatizada de Riesgo de Suicidio, un instrumento de red neural de retropropagación (CSRS-BP)
- Author
-
R. Kurs, Michael S. Ritsner, A. Ponizovsky, Ilan Modai, and Shalom Mendel
- Subjects
03 medical and health sciences ,0302 clinical medicine ,Psychology ,030217 neurology & neurosurgery ,030227 psychiatry - Abstract
ResumenAntecedentes:Los intentos de suicidio médicamente graves se han reconocido como el predictor más importante de suicidio. Recientemente se ha encontrado que la Escala Informatizada de Riesgo de Suicidio basada en redes neurales de retropropagación (CSRS-BP) es eficaz en la detección de historias clínicas de pacientes que realizaron intentos de suicidio médicamente graves (ISMG).Objetivos:Validar la CSRS-BP: 1) utilizándola con pacientes en lugar de con historias clínicas; 2) comparando la capacidad de psiquiatras expertos para detectar ISMG utilizando la lista de la CSRS, y 3) comparando los resultados del Estimador de Riesgo para el Suicidio (RES) y la Escala de autoevaluación de Riesgo de Suicidio (SRS) con la CSRS-BP.Métodos:Profesionales clínicos diagnosticaron a 250 pacientes psiquiátricos hospitalizados (35 con ISMG y 215 sin ISMG) utilizando la SCID del DSM IV. Tres psiquiatras expertos cumplimentaron la lista de la CSRS y el RES para cada paciente, y los pacientes rellenaron la escala de evaluación de autoinforme SRS. La CSRS-BP se pasó en máquina para cada paciente. Otros cinco psiquiatras expertos evaluaron las listas de la CSRS y estimaron la probabilidad de ISMG para cada paciente. Se hicieron comparaciones de las tasas de sensibilidad y especificidad entre la CSRS-BP, las escalas de evaluación y los expertos.Resultados:Inicialmente, la CSRS-BP, el RES, la SRS y los expertos obtuvieron malos resultados. Aunque las tasas de sensibilidad y especificidad mejoraron significativamente (de dos a cuatro veces) después de la inclusión de información con respecto al número de intentos previos de suicidio en el conjunto de datos de entrada, los resultados todavía no eran significativos.Conclusiones:La CSRS-BP, que tuvo mucho éxito en la detección de historias clínicas de pacientes con ISMG, no detectó a los pacientes con ISMG en entrevistas cara a cara. La información con respecto a los intentos de suicidio anteriores es un predictor importante de ISMG, pero es insuficiente para su detección en los pacientes individuales. La tasa de detección de la SRS y la escala RES fue también mala y, por tanto, no pudieron identificar a los pacientes con ISMG o utilizarse para validar la CSRS-BP.
- Published
- 2002
45. Impact of antipsychotic agents and their side effects on the quality of life in schizophrenia
- Author
-
Rena Kurs and Michael S. Ritsner
- Subjects
medicine.medical_specialty ,business.industry ,Health Policy ,medicine.medical_treatment ,Outcome measures ,MEDLINE ,General Medicine ,medicine.disease ,Quality of life ,Schizophrenia ,medicine ,Pharmacology (medical) ,Psychiatry ,Adverse effect ,Subjective quality ,business ,Antipsychotic ,Psychosocial - Abstract
Schizophrenia is the most chronic and disabling of mental illnesses and it imposes a disproportionately large economic burden on society. In addition to symptom reduction and cost-effectiveness, quality of life is becoming a critical outcome measure for the efficacy of antipsychotic agents in the treatment of schizophrenia patients. This review concentrates on the influences of antipsychotic agents and their side effects on quality of life of schizophrenia patients. Of the 182 papers elicited in a comprehensive Medline search from 1996-2002, we found only 21 significant papers (11.5%) reporting findings concerning the effect of antipsychotic agents on quality of life of schizophrenia patients. Very few studies directly examined the impact of side effects on quality of life ratings of schizophrenia patients. To date, there is no clear evidence that in the long-term, atypical antipsychotics are more effective or are better tolerated than typical antipsychotics. This review suggests that side effects of antipsychotic agents influence subjective quality of life of schizophrenia patients significantly less than clinical and psychosocial factors. The patient's subjective response to side effects of medication is more predictive of quality of life than the number of those effects. We discuss both patients' and clinicians' perceptions of side effects and quality of life, which should be considered in the evaluation of the efficacy of antipsychotic agents.
- Published
- 2002
46. An association of CAG repeats at the KCNN3 locus with symptom dimensions of schizophrenia
- Author
-
Abraham Weizman, Ruth Navon, Michael S. Ritsner, Hana Ziv, Tami Halperin, Ilan Modai, and Sharon Amir
- Subjects
Adult ,Male ,Psychosis ,Potassium Channels ,Multivariate analysis ,Adolescent ,Genotype ,Small-Conductance Calcium-Activated Potassium Channels ,Locus (genetics) ,Polymerase Chain Reaction ,Severity of Illness Index ,Potassium Channels, Calcium-Activated ,Gene Frequency ,Trinucleotide Repeats ,mental disorders ,medicine ,Humans ,Allele ,Biological Psychiatry ,Aged ,DNA Primers ,Psychiatric Status Rating Scales ,Genetics ,Negative symptom ,Middle Aged ,medicine.disease ,Blotting, Southern ,Schizophrenia ,Female ,Psychology - Abstract
Background: In 1999 Cardno et al reported that long CAG repeats in the calcium-activated potassium channel gene hSKCa3/KCNN3 are associated with higher negative symptom dimension scores in schizophrenia patients. There has been no attempt to replicate the results. In this study, we investigated whether a symptom polymorphism of schizophrenia is associated with both the CAG repeat numbers and the difference in allele sizes. Methods: We tested the association of CAG repeats with symptom models of schizophrenia in 117 unrelated Jewish patients. A multivariate analysis (MANOVA) of two models of schizophrenia with the repeat distribution and the difference in allele sizes was performed. Results: We found a significant positive association of the number of CAG repeats with negative syndrome, anergia, activation, and paranoid symptoms. In addition, nonparanoid schizophrenia patients who had differences in allele sizes were characterized by earlier onset of illness. Conclusions: The study supports the hypothesis that the combined effect of long CAG repeats and the differences in allele sizes contribute to symptom expression of schizophrenia, particularly on the anergia-activation-paranoid axis.
- Published
- 2002
47. Validation of the Computerized Suicide Risk Scale – a backpropagation neural network instrument (CSRS-BP)
- Author
-
Michael S. Ritsner, R. Kurs, Ilan Modai, Shalom Mendel, and A. Ponizovsky
- Subjects
Adult ,medicine.medical_specialty ,Psychometrics ,MEDLINE ,Suicide, Attempted ,Test validity ,Risk Assessment ,Sensitivity and Specificity ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Surveys and Questionnaires ,medicine ,Humans ,Psychiatry ,Aged ,Aged, 80 and over ,Psychiatric Status Rating Scales ,business.industry ,Mental Disorders ,Middle Aged ,Assessment scale ,Checklist ,Suicide risk scale ,030227 psychiatry ,Psychiatry and Mental health ,Emergency medicine ,Neural Networks, Computer ,Detection rate ,business ,Risk assessment ,030217 neurology & neurosurgery - Abstract
SummaryBackgroundMedically serious suicide attempts have been recognized as the most important predictor of suicide. The Computerized Suicide Risk Scale based on backpropagation neural networks (CSRS-BP) has been recently found efficient in the detection of records of patients who performed medically serious suicide attempts (MSSA).ObjectivesTo validate the CSRS-BP by: 1) using the CSRS-BP with patients instead of records; 2) comparing the ability of expert psychiatrists to detect MSSA, using the CSRS checklist; and 3) comparing the results of the Risk Estimator for Suicide (RES) and the self-rating Suicide Risk Scale (SRS) with the CSRS-BP.MethodsTwo hundred fifty psychiatric inpatients (35 MSSA and 215 non-MSSA) were diagnosed by clinicians using the SCID DSM-IV. Three expert psychiatrists completed the CSRS checklist, and the RES for each patient, and the patients completed the self-report SRS assessment scale. The CSRS-BP was run for each patient. Five other expert psychiatrists assessed the CSRS checklists and estimated the probability of MSSA for each patient. Comparisons of sensitivity and specificity rates between CSRS-BP, assessment scales and experts were done.ResultsInitially, the CSRS-BP, RES, SRS, and experts performed poorly. Although sensitivity and specificity rates significantly improved (two to four times) after the inclusion of information regarding the number of previous suicide attempts in the input data set, results still remained insignificant.ConclusionsThe CSRS-BP, which was very successful in the detection of MSSA patient records, failed to detect MSSA patients in face-to-face interviews. Information regarding previous suicide attempts is an important MSSA predictor, but remains insufficient for the detection of MSSA in individual patients. The detection rate of the SRS and RES scales was also poor and could therefore not identify MSSA patients or be used to validate the CSRS-BP.
- Published
- 2002
48. Schizophrenic patients who smoke have a faster finger tapping rate than non-smokers
- Author
-
Nili Shlomo, Ilan Modai, Henry Silver, Michael S. Ritsner, Christoph Hiemke, and M. L. Rao
- Subjects
Adult ,Male ,Nicotine ,medicine.medical_specialty ,Patients ,Movement ,medicine.medical_treatment ,Clinical state ,Fingers ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Nicotinic Agonists ,Antipsychotic ,Psychiatry ,Biological Psychiatry ,Pharmacology ,Smoke ,Analysis of Variance ,Smoking ,Middle Aged ,medicine.disease ,Psychiatry and Mental health ,Neurology ,Schizophrenia ,Finger tapping ,Plasma concentration ,Smoking status ,Neurology (clinical) ,Psychology ,Psychomotor Performance ,medicine.drug - Abstract
The increased rate of smoking in schizophrenia patients remains unexplained and may reflect attempts at self-treatment. The effect sought from smoking may be related to nicotine's stimulating action. We tested this hypothesis by examining the relationship between smoking status and finger tapping rate, a measure of central processing, in schizophrenia patients treated with atypical antipsychotics. Smokers showed significantly faster finger tapping rates than non-smokers. This was not related to clinical state, illness chronicity, medication side-effects, antipsychotic dose or plasma concentrations. Nicotine can improve central processing in medicated schizophrenia patients and this may constitute part of the incentive for smoking.
- Published
- 2002
49. Clinical Evaluation of Prior Suicide Attempts and Suicide Risk in Psychiatric Inpatients
- Author
-
C. Bernat, Rena Kurs, Ilan Modai, O. Rivkin, Michael S. Ritsner, Jack Hadjez, Yael Ratner, Alexander M. Ponizovsky, S. Hirschmann, and D. Gelber
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Decision Making ,MEDLINE ,Poison control ,Suicide, Attempted ,Suicide prevention ,Occupational safety and health ,Risk Factors ,Injury prevention ,medicine ,Humans ,Decision-making ,Psychiatry ,Aged ,Aged, 80 and over ,business.industry ,Mental Disorders ,Human factors and ergonomics ,Middle Aged ,Hospitalization ,Psychiatry and Mental health ,Female ,business ,Decision model ,Clinical psychology - Abstract
Summary: Background: In practice psychiatrists rely on their own experience and intuition to evaluate the suicide potential of individual patients, but the algorithms for the decision-making process remain unclear. Objectives: (1) to establish models for the decision making process for evaluating suicide risk; (2) to simulate the impact of information concerning the number of previous suicide attempts on the clinician's ability to detect patients who performed medically serious suicide attempts (MSSAs). Methods: Four decision models (linear, dichotomized, hyperbolic, and undifferentiated) depicting the influence of the number of previous suicide attempts on the clinician's recognition of MSSAs in 250 psychiatric inpatients were elicited and tested by a series of discriminant analyses. Results: The dichotomized model (“all or none”) was found to be the most efficient in detecting medically serious suicide attempts. Conclusion: The “all or none” paradigm seems to be the most appropriate way to evaluate the weight of previous suicide attempts in the decision-making process identifying medically serious suicide attempt patients.
- Published
- 2002
50. [Untitled]
- Author
-
Ilan Modai, Michael S. Ritsner, Alexander M. Ponizovsky, H. Kostizky, and Rena Kurs
- Subjects
medicine.medical_specialty ,Psychometrics ,Public health ,Public Health, Environmental and Occupational Health ,Mental health ,humanities ,Correlation ,Quality of life ,Severity of illness ,medicine ,medicine.symptom ,Psychology ,Psychiatry ,Mania ,Depression (differential diagnoses) ,Clinical psychology - Abstract
Although many quality of life (QOL) scales have been developed, comparison of specific QOL instruments is lacking. We compared the psychometric properties of two QOL measures in parallel samples of mentally disturbed and non-patient subjects. We simultaneously administered the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) and self-report items of the Lancashire Quality of Life Profile (LQOLP) to 199 patients with severe mental disorders and 175 non-patients. The patients were evaluated with psychiatric rating scales. We identified five concordant domains, and five instrument-specific domains for the LQOLP and four for the Q-LES-Q. The Q-LES-Q provides better psychometric properties than the LQOLP in both samples. Both instruments show a good capacity to evaluate QOL and discriminate between the patients and non-patient controls. Within the patient sample, both QOL measures showed similarly negative correlations with severity of depression, but not mania, positive, negative, and general symptomatology. Both instruments proved to be mental health related, but neither was mental-disorder specific. Despite the acceptable psychometric properties and correlation of general QOL indices, similar QOL domains proved to be instrument specific and not sufficiently compatible. These discrepancies should be considered when comparing evaluations from similar domains in these QOL scales.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.